Gaixiu Su1, Jianming Lai2, Jia Zhu1, Dan Zhang1, Jun Hou1, Yingjie Xu1, Zhixuan Zhou1. 1. Department of Rheumatology and Immunology, Capital Institute of Pediatrics, No.2 Yabao Road, Chaoyang District, Beijing, 100020, China. 2. Department of Rheumatology and Immunology, Capital Institute of Pediatrics, No.2 Yabao Road, Chaoyang District, Beijing, 100020, China. laijm99@sina.com.
Abstract
OBJECTIVE AND DESIGN: We studied five cases of PID-related monogenic lupus to explore the characteristics. MATERIAL OR SUBJECTS: Among 42 cases of PID patients between 2017-2020, 5 patients were diagnosed as PID-related monogenic lupus, including 2 males and 3 females, with age range from 2 years 3 months to 13 years old. TREATMENTS: DMARDs, biological agents and stem cell transplantation were used to treat different patients. METHODS: We collected the clinical observation indicators, auxiliary examination and treatment of the five patients. RESULTS: Patient 1 was diagnosed with monogenic lupus secondary to severe combined immunodeficiency and received prednisone and methotrexate treatment. Patient 2 was diagnosed with monogenic lupus secondary to activated phosphoinositide 3-kinase δ syndrome. Allogeneic stem cell transplantation was conducted. Patient 3 was diagnosed with monogenic lupus secondary to RAS-associated lymphoproliferative disease. The child was treated with prednisone and rituximab. Patient 4 was diagnosed with monogenic lupus secondary to PSTPIP1-associated myeloid-related proteinaemia inflammatory syndrome. The child was given methylprednisolone, methotrexate, and infliximab. Patient 5 was diagnosed with monogenic lupus secondary to A20 haploinsufficiency. The child was treated with methylprednisolone and infliximab. CONCLUSIONS: Multiple PIDs can lead to monogenic lupus. Different PID-related monogenic lupus has different suitable targeted drugs.
OBJECTIVE AND DESIGN: We studied five cases of PID-related monogenic lupus to explore the characteristics. MATERIAL OR SUBJECTS: Among 42 cases of PID patients between 2017-2020, 5 patients were diagnosed as PID-related monogenic lupus, including 2 males and 3 females, with age range from 2 years 3 months to 13 years old. TREATMENTS: DMARDs, biological agents and stem cell transplantation were used to treat different patients. METHODS: We collected the clinical observation indicators, auxiliary examination and treatment of the five patients. RESULTS: Patient 1 was diagnosed with monogenic lupus secondary to severe combined immunodeficiency and received prednisone and methotrexate treatment. Patient 2 was diagnosed with monogenic lupus secondary to activated phosphoinositide 3-kinase δ syndrome. Allogeneic stem cell transplantation was conducted. Patient 3 was diagnosed with monogenic lupus secondary to RAS-associated lymphoproliferative disease. The child was treated with prednisone and rituximab. Patient 4 was diagnosed with monogenic lupus secondary to PSTPIP1-associated myeloid-related proteinaemia inflammatory syndrome. The child was given methylprednisolone, methotrexate, and infliximab. Patient 5 was diagnosed with monogenic lupus secondary to A20 haploinsufficiency. The child was treated with methylprednisolone and infliximab. CONCLUSIONS: Multiple PIDs can lead to monogenic lupus. Different PID-related monogenic lupus has different suitable targeted drugs.
Authors: Florence A Aeschlimann; Ezgi D Batu; Scott W Canna; Ellen Go; Ahmet Gül; Patrycja Hoffmann; Helen L Leavis; Seza Ozen; Daniella M Schwartz; Deborah L Stone; Annet van Royen-Kerkof; Daniel L Kastner; Ivona Aksentijevich; Ronald M Laxer Journal: Ann Rheum Dis Date: 2018-01-09 Impact factor: 19.103
Authors: Dirk Holzinger; Selina Kathleen Fassl; Wilco de Jager; Peter Lohse; Ute F Röhrig; Marco Gattorno; Alessia Omenetti; Sabrina Chiesa; Francesca Schena; Judith Austermann; Thomas Vogl; Douglas B Kuhns; Steven M Holland; Carlos Rodríguez-Gallego; Ricardo López-Almaraz; Juan I Arostegui; Elena Colino; Rosa Roldan; Smaragdi Fessatou; Bertrand Isidor; Sylvaine Poignant; Koichi Ito; Hans-Joerg Epple; Jonathan A Bernstein; Michael Jeng; Jennifer Frankovich; Geraldina Lionetti; Joseph A Church; Peck Y Ong; Mona LaPlant; Mario Abinun; Rod Skinner; Venetia Bigley; Ulrich J Sachs; Claas Hinze; Esther Hoppenreijs; Jan Ehrchen; Dirk Foell; Jae Jin Chae; Amanda Ombrello; Ivona Aksentijevich; Cord Sunderkoetter; Johannes Roth Journal: J Allergy Clin Immunol Date: 2015-05-27 Impact factor: 10.793
Authors: Jocelyn R Farmer; Zsofia Foldvari; Boglarka Ujhazi; Suk See De Ravin; Karin Chen; Jack J H Bleesing; Catharina Schuetz; Waleed Al-Herz; Roshini S Abraham; Avni Y Joshi; Beatriz T Costa-Carvalho; David Buchbinder; Claire Booth; Andreas Reiff; Polly J Ferguson; Asghar Aghamohammadi; Hassan Abolhassani; Jennifer M Puck; Mehdi Adeli; Caterina Cancrini; Paolo Palma; Alice Bertaina; Franco Locatelli; Gigliola Di Matteo; Raif S Geha; Maria G Kanariou; Lilia Lycopoulou; Marianna Tzanoudaki; John W Sleasman; Suhag Parikh; Gloria Pinero; Bernard M Fischer; Ghassan Dbaibo; Ekrem Unal; Turkan Patiroglu; Musa Karakukcu; Khulood Khalifa Al-Saad; Meredith A Dilley; Sung-Yun Pai; Cullen M Dutmer; Erwin W Gelfand; Christoph B Geier; Martha M Eibl; Hermann M Wolf; Lauren A Henderson; Melissa M Hazen; Carmem Bonfim; Beata Wolska-Kuśnierz; Manish J Butte; Joseph D Hernandez; Sarah K Nicholas; Polina Stepensky; Shanmuganathan Chandrakasan; Maurizio Miano; Emma Westermann-Clark; Vera Goda; Gergely Kriván; Steven M Holland; Olajumoke Fadugba; Sarah E Henrickson; Ahmet Ozen; Elif Karakoc-Aydiner; Safa Baris; Ayca Kiykim; Robbert Bredius; Birgit Hoeger; Kaan Boztug; Olga Pashchenko; Benedicte Neven; Despina Moshous; Jean-Pierre de Villartay; Ahmed Aziz Bousfiha; Harry R Hill; Luigi D Notarangelo; Jolan E Walter Journal: J Allergy Clin Immunol Pract Date: 2019-03-12
Authors: Giuliana Giardino; Vera Gallo; Rosaria Prencipe; Giovanni Gaudino; Roberta Romano; Marco De Cataldis; Paola Lorello; Loredana Palamaro; Chiara Di Giacomo; Donatella Capalbo; Emilia Cirillo; Roberta D'Assante; Claudio Pignata Journal: Front Pediatr Date: 2016-10-06 Impact factor: 3.418